Roche Holding AG banner

Roche Holding AG
F:RHO

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
F:RHO
Watchlist
Price: 360 EUR 0.84% Market Closed
Market Cap: €307.5B

Multiples-Based Value

RHO price has not been updated for more than 3 years. This may indicate that the stock has been delisted.

The Multiples-Based Value for Roche Holding AG (RHO) under the Base Case is hidden EUR. Compared with the current market price of 360 EUR, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RHO Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

RHO Competitors Multiples
Roche Holding AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Roche Holding AG
F:RHO
248.4B EUR 4.1 19.7 11.6 13.1
US
Eli Lilly and Co
NYSE:LLY
883.9B USD 13.6 42.8 28.9 30.8
US
Johnson & Johnson
NYSE:JNJ
585.2B USD 6.2 21.8 15.2 18.6
UK
AstraZeneca PLC
LSE:AZN
237.5B GBP 5.4 31.2 17.2 24.2
US
Merck & Co Inc
NYSE:MRK
299.1B USD 4.6 16.4 10.1 12.3
CH
Novartis AG
SIX:NOVN
235.8B CHF 5.4 21.8 13.5 17.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
161B USD 2.6 20.7 7.9 10.5
US
Bristol-Myers Squibb Co
NYSE:BMY
120B USD 2.5 17 7.2 8.8
FR
Sanofi SA
PAR:SAN
99.8B EUR 2.1 12.8 10.6 10.6
P/E Multiple
Earnings Growth PEG
CH
Roche Holding AG
F:RHO
Average P/E: 21.4
19.7
14%
1.4
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
31.2
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
CH
Novartis AG
SIX:NOVN
21.8
14%
1.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
FR
Sanofi SA
PAR:SAN
12.8
16%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Roche Holding AG
F:RHO
Average EV/EBITDA: 45.9
11.6
6%
1.9
US
Eli Lilly and Co
NYSE:LLY
28.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
UK
AstraZeneca PLC
LSE:AZN
17.2
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.9
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
FR
Sanofi SA
PAR:SAN
10.6
19%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Roche Holding AG
F:RHO
Average EV/EBIT: 99.7
13.1
6%
2.2
US
Eli Lilly and Co
NYSE:LLY
30.8
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
24.2
21%
1.2
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2.1
CH
Novartis AG
SIX:NOVN
17.3
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
FR
Sanofi SA
PAR:SAN
10.6
12%
0.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett